$16.10
0.92%
Nasdaq, Nov 19, 04:00 pm EST. Closed.
ISIN
US52490G1022
Symbol
LEGN

Legend Biotech Corp - ADR Stock News

Neutral
●
GlobeNewsWire
●
10 days ago
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million Half of CARTITUDE-2 Cohort A patients remained alive and progression-free without further anti-myeloma treatment five years after a single CARVYKTI ® infusion, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line...
Neutral
●
GlobeNewsWire
●
16 days ago
New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells BRIDGEWATER, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ...
Neutral
●
GlobeNewsWire
●
about one month ago
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance  IND clearance supports planned U.S. Phase 1/2 study and advances Legend Biotech's in vivo cell engineering platform BRIDGEWATER, N.J., Oct. 15, ...
Neutral
●
GlobeNewsWire
●
about 2 months ago
Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE...
Neutral
●
GlobeNewsWire
●
about 2 months ago
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
Positive
●
Reuters
●
2 months ago
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an ​industry veteran to steer its expansion beyond blockbuster ‌cancer therapy Carvykti.
Neutral
●
GlobeNewsWire
●
2 months ago
BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today